IINN vs AVAV vs LUNG vs SPRO vs GMED

For growth investors, Globus Medical, Inc.

(GMED) is the stronger pick with 16. 7% revenue growth year-over-year, versus -53. 8% for Spero Therapeutics, Inc. (SPRO). Globus Medical, Inc. (GMED) offers the better valuation at 21. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate AeroVironment, Inc. (AVAV) a "Buy" — based on 28 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Globus Medical, Inc.

(GMED) is the cheapest at 21. 7x versus AeroVironment, Inc. at 108. 5x. On forward P/E, Spero Therapeutics, Inc. is actually cheaper at 3. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AeroVironment, Inc.

(AVAV) delivered a total return of +53. 7%, compared to -97. 0% for Pulmonx Corporation (LUNG). Over 10 years, the gap is even starker: AVAV returned +498. 3% versus LUNG's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Spero Therapeutics, Inc.

(SPRO) is the lower-risk stock at 0. 90β versus Pulmonx Corporation's 2. 36β — meaning LUNG is approximately 161% more volatile than SPRO relative to the S&P 500. On balance sheet safety, Globus Medical, Inc. (GMED) carries a lower debt/equity ratio of 3% versus 104% for Pulmonx Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Globus Medical, Inc.

(GMED) is pulling ahead at 16. 7% versus -53. 8% for Spero Therapeutics, Inc. (SPRO). On earnings-per-share growth, the picture is similar: Globus Medical, Inc. grew EPS 422. 7% year-over-year, compared to -395. 3% for Spero Therapeutics, Inc.. Over a 3-year CAGR, SPRO leads at 150. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Globus Medical, Inc.

(GMED) is the more profitable company, earning 18. 3% net margin versus -43. 7% for Inspira Technologies Oxy B. H. N. Ltd. — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IINN leads at 45. 1% versus -152. 9% for SPRO. At the gross margin level — before operating expenses — LUNG leads at 74. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Spero Therapeutics, Inc.

(SPRO) trades at 3. 7x forward P/E versus 58. 4x for AeroVironment, Inc. — 54. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AVAV: 104. 3% to $343. 60.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Spero Therapeutics, Inc.

(SPRO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90)). Pulmonx Corporation (LUNG) carries a higher beta of 2. 36 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SPRO: -78. 2%, LUNG: -96. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (IINN (Healthcare) and AVAV (Industrials) and LUNG (Healthcare) and SPRO (Healthcare) and GMED (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IINN is a small-cap quality compounder stock; AVAV is a small-cap quality compounder stock; LUNG is a small-cap quality compounder stock; SPRO is a small-cap quality compounder stock; GMED is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.